Matrine reduces the proliferation of A549 cells via the p53/p21/PCNA/eIF4E signaling pathway

Lu,Zhiyan; Xiao,Youzhang; Liu,Xing; Zhang,Zaipeng; Xiao,Feng; Bi,Yongyi

doi:10.3892/mmr.2017.6331

Matrine reduces the proliferation of A549 cells via the p53/p21/PCNA/eIF4E signaling pathway

Authors:
- Zhiyan Lu
- Youzhang Xiao
- Xing Liu
- Zaipeng Zhang
- Feng Xiao
- Yongyi Bi
View Affiliations

Affiliations: Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Key Laboratory of Pharmaceutical Biotechnology, School of Medicine, Jinggangshan University, Ji'an, Jiangxi 343000, P.R. China, Hubei Biomass-resource Chemistry and Environmental Biotechnology Key Laboratory, School of Public Health, Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: March 16, 2017 https://doi.org/10.3892/mmr.2017.6331
Pages: 2415-2422
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate how matrine affects the proliferation of A549 human lung adenocarcinoma cells via the p53/p21/proliferating cell nuclear antigen (PCNA)/eukaryotic translation initiation factor 4E (eIF4E) signaling pathway. The effect of different concentrations of matrine on the proliferation of A549 cells was investigated using a 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide (MTT) assay. The migration of A549 cells following exposure to varied concentrations of matrine was detected using a Transwell cell migration assay. The effect of 240 mg/l matrine on the apoptotic rate of A549 cells was determined using flow cytometry. The change in the mRNA and protein expression levels of p53, p21, PCNA and eIF4E following exposure to matrine were detected using reverse transcription‑quantitative polymerase chain reaction and western blotting, respectively. The increase of matrine from 60‑240 mg/l led to reduced cell migration and inhibition of A549 cell proliferation. The apoptotic rate of A549 cells when treated with 240 mg/l matrine was significantly different when compared with the untreated control. The mRNA expression levels of p53 and p21 in the group treated with 240 mg/l matrine were significantly higher compared with the control group. The mRNA expression levels of PCNA and eIF4E were significantly lower in the 240 mg/l matrine‑treated group compared with the control. The protein expression levels of p53 and p21 were significantly higher in the 240 mg/l matrine group compared with the control group. Treatment with 240 mg/l matrine reduced the protein expression levels of PCNA and eIF4E. Matrine also reduced the migration ability of A549 cells and inhibited their proliferation, which may be associated with the overexpression of p53 and p21, and the reduction of PCNA and eIF4E expression levels.

View Figures

View References

1	Kajatt Amorin E: Lung cancer: A review of current knowledge, diagnostic methods and therapeutic perspectives. Rev Peru Med Exp Salud Publica. 30:85–92. 2013.(In Spanish). PubMed/NCBI
2	Spaans JN and Goss GD: Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. Front Oncol. 4:1902014. View Article : Google Scholar : PubMed/NCBI
3	Lu ZG, Li MH, Wang JS, Wei DD, Liu QW and Kong LY: Developmental toxicity and neurotoxicity of two matrine-type alkaloids, matrine and sophocarpine, in zebrafish (Danio rerio) embryos/larvae. Reprod Toxicol. 47:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
4	Liu YQ, Li Y, Qin J, Wang Q, She YL, Luo YL, He JX, Li JY and Xie XD: Matrine reduces proliferation of human lung cancer cells by inducing apoptosis and changing miRNA expression profiles. Asian Pac J Cancer Prev. 15:2169–2177. 2014. View Article : Google Scholar : PubMed/NCBI
5	Yang CL, Liu SS, Ma YG, Liu YY, Xue YX and Huang B: The influence of intraoperative pleural perfusion with matrine-cisplatin or cisplatin on stromal cell-derived factor-1 in non-small cell lung cancer patients with subclinical pleural metastasis. Med Oncol. 29:574–581. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rogler CE and Chisari FV: Cellular and molecular mechanisms of hepatocarcinogenesis. Semin Liver Dis. 12:265–278. 1992. View Article : Google Scholar : PubMed/NCBI
7	Dong M, Nio Y, Yamasawa K, Toga T, Yue L and Harada T: p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J Surg Oncol. 82:111–120. 2003. View Article : Google Scholar : PubMed/NCBI
8	Matsui TA, Sowa Y, Murata H, Takagi K, Nakanishi R, Aoki S, Yoshikawa M, Kobayashi M, Sakabe T, Kubo T and Sakai T: The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line. Int J Oncol. 31:915–922. 2007.PubMed/NCBI
9	Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, et al: Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21 (WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 124:1637–1644. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yeo D, He H, Baldwin GS and Nikfarjam M: The role of p21-activated kinases in pancreatic cancer. Pancreas. 44:363–369. 2015. View Article : Google Scholar : PubMed/NCBI
11	Xie D, Lan L, Huang K, Chen L, Xu C, Wang R, Shi Y, Wu X, Wang L, Liu Y and Lu B: Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients. Oncol Rep. 32:2517–2526. 2014.PubMed/NCBI
12	Freund G, Desplancq D, Stoessel A, Weinsanto R, Sibler AP, Robin G, Martineau P, Didier P, Wagner J and Weiss E: Generation of an intrabody-based reagent suitable for imaging endogenous proliferating cell nuclear antigen in living cancer cells. J Mol Recognit. 27:549–558. 2014. View Article : Google Scholar : PubMed/NCBI
13	Halvorsen OJ: Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers. APMIS. Suppl. 5–62. 2008.
14	Liu Y, Bi T, Wang G, Dai W, Wu G, Qian L, Gao Q and Shen G: Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways. Naunyn Schmiedebergs Arch Pharmacol. 388:295–304. 2015. View Article : Google Scholar : PubMed/NCBI
15	Chakravarthy R, Clemens MJ, Pirianov G, Perdios N, Mudan S, Cartwright JE and Elia A: Role of the eIF4E binding protein 4E-BP1 in regulation of the sensitivity of human pancreatic cancer cells to TRAIL and celastrol-induced apoptosis. Biol Cell. 105:414–429. 2013. View Article : Google Scholar : PubMed/NCBI
16	Martineau Y, Azar R, Müller D, Lasfargues C, El Khawand S, Anesia R, Pelletier J, Bousquet C and Pyronnet S: Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene. 33:1367–1374. 2014. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Bi W, Tian M and Row KH: Solid-phase extraction of matrine and oxymatrine from Sophora flavescens Ait using amino-imidazolium polymer. J Sep Sci. 33:1739–1745. 2010. View Article : Google Scholar : PubMed/NCBI
19	Cho CH, Chuang CY and Chen CF: Study of the antipyretic activity of matrine. A lupin alkaloid isolated from Sophora subprostrata. Planta Med. 343–345. 1986. View Article : Google Scholar : PubMed/NCBI
20	Wang H, Guo S, Qian D, Qian Y and Duan JA: Comparative analysis of quinolizidine alkaloids from different parts of Sophora alopecuroides seeds by UPLC-MS/MS. J Pharm Biomed Anal. 67–68:16–21. 2012. View Article : Google Scholar
21	Ou X, Chen Y, Cheng X, Zhang X and He Q: Potentiation of resveratrol-induced apoptosis by matrine in human hepatoma HepG2 cells. Oncol Rep. 32:2803–2809. 2014.PubMed/NCBI
22	Niu H, Zhang Y, Wu B, Zhang Y, Jiang H and He P: Matrine induces the apoptosis of lung cancer cells through downregulation of inhibitor of apoptosis proteins and the Akt signaling pathway. Oncol Rep. 32:1087–1093. 2014.PubMed/NCBI
23	Li H, Xie S, Liu X, Wu H, Lin X, Gu J, Wang H and Duan Y: Matrine alters microRNA expression profiles in SGC-7901 human gastric cancer cells. Oncol Rep. 32:2118–2126. 2014.PubMed/NCBI
24	Zhang S, Cheng B, Li H, Xu W, Zhai B, Pan S, Wang L, Liu M and Sun X: Matrine inhibits proliferation and induces apoptosis of human colon cancer LoVo cells by inactivating Akt pathway. Mol Biol Rep. 41:2101–2108. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zhang L, Wang T, Wen X, Wei Y, Peng X, Li H and Wei L: Effect of matrine on HeLa cell adhesion and migration. Eur J Pharmacol. 563:69–76. 2007. View Article : Google Scholar : PubMed/NCBI
26	Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J, Zhang S, Wu J, Yu K and Han Y: Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS One. 7:e468532012. View Article : Google Scholar : PubMed/NCBI
27	Li Y, Zhang ZN, Zhao HM, Tong ZC, Yang J, Wang H and Liang XJ: Matrine inhibits the invasive properties of human osteosarcoma cells by downregulating the ERK-NF-kB pathway. Anticancer Drugs. 25:1035–1043. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhang S, Qi J, Sun L, Cheng B, Pan S, Zhou M and Sun X: Matrine induces programmed cell death and regulates expression of relevant genes based on PCR array analysis in C6 glioma cells. Mol Biol Rep. 36:791–799. 2009. View Article : Google Scholar : PubMed/NCBI
29	Xie M, He G, Wang R, Shi S, Chen J, Ye Y, Xie L, Yi X and Tang A: Matrine-induced apoptosis of human nasopharyngeal carcinoma cells via in vitro vascular endothelial growth factor-A/extracellular signal-regulated kinase1/2 pathway inactivation. Horm Metab Res. 46:556–560. 2014. View Article : Google Scholar : PubMed/NCBI
30	Keith RL: Chemoprevention of lung cancer. Proc Am Thorac Soc. 6:187–193. 2009. View Article : Google Scholar : PubMed/NCBI
31	Saika K and Sobue T: Lung cancer: Progress in diagnosis and treatments. Topics I. Epidemiology and pathogenesis; 1. Epidemiology, prevention and screening. Nihon Naika Gakkai Zasshi. 103:1255–1260. 2014.(In Japanese). View Article : Google Scholar : PubMed/NCBI
32	Nykainen A, Räsänen J, Salo J and Sihvo E: Thoracoscopic surgery of lung cancer. Duodecim. 130:145–151. 2014.(In Finnish). PubMed/NCBI
33	Pflaum J, Schlosser S and Müller M: p53 family and cellular stress responses in cancer. Front Oncol. 4:2852014. View Article : Google Scholar : PubMed/NCBI
34	Farnebo M, Bykov VJ and Wiman KG: The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 396:85–89. 2010. View Article : Google Scholar : PubMed/NCBI
35	Cadwell C and Zambetti GP: The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene. 277:15–30. 2001. View Article : Google Scholar : PubMed/NCBI
36	Marone M, Bonanno G, Rutella S, Leone G, Scambia G and Pierelli L: Survival and cell cycle control in early hematopoiesis: Role of bcl-2 and the cyclin dependent kinase inhibitors P27 and P21. Leuk Lymphoma. 43:51–57. 2002. View Article : Google Scholar : PubMed/NCBI
37	Saegusa M, Hashimura M, Suzuki E, Yoshida T and Kuwata T: Transcriptional up-regulation of Sox9 by NF-kB in endometrial carcinoma cells, modulating cell proliferation through alteration in the p14 (ARF)/p53/p21 (WAF1) pathway. Am J Pathol. 181:684–692. 2012. View Article : Google Scholar : PubMed/NCBI
38	Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K, Ward AJ, Raj A, Lee JT, Sharp PA and Jacks T: LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell. 54:777–790. 2014. View Article : Google Scholar : PubMed/NCBI
39	Chen W, Yoshida S, Ohara N, Matsuo H, Morizane M and Maruo T: Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly (adenosine 5′-diphosphate-ribose) polymerase expression in cultured human leiomyoma cells. J Clin Endocrinol Metab. 90:884–892. 2005. View Article : Google Scholar : PubMed/NCBI
40	Gao X, Dan S, Xie Y, Qin H, Tang D, Liu X, He QY and Liu L: 14-3-3ζ reduces DNA damage by interacting with and stabilizing proliferating cell nuclear antigen. J Cell Biochem. 116:158–169. 2015. View Article : Google Scholar : PubMed/NCBI
41	Oyama T, Mitsudomi T, Mizoue T, Ohgami A, Osaki T, Nakanishi R and Yasumoto K: Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Surg Oncol. 4:83–89. 1995. View Article : Google Scholar : PubMed/NCBI
42	Sonenberg N: eIF4E, the mRNA cap-binding protein: From basic discovery to translational research. Biochem Cell Biol. 86:178–183. 2008. View Article : Google Scholar : PubMed/NCBI
43	Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, Ramalingam SS, Khuri FR and Sun SY: Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 13:272–280. 2012. View Article : Google Scholar : PubMed/NCBI